



Pressure BioSciences, Inc.

Ticker: P BIO (OTCQB)

Corporate Profile

as of March 28, 2017

Pressure BioSciences, Inc. (OTCQB: P BIO) is a medical research products and technology company.

PBI has developed and patented a cutting-edge technology platform that can exquisitely control sample preparation processes including the wide range of activities that precede many forms of scientific analysis.

PBI's development and sales efforts are in the biomarker discovery, drug discovery/design, and forensics areas.

For Fiscal 2016, PBI reported an increase of annual product and service revenue of \$384,758 dollars, a 27% growth over the prior year.

One of the major improvements PBI has incorporated is in the area of its marketing its products. PBI has significantly expanded the Company's focus and capabilities in marketing and sales, which will significantly push the Firm forward for the remainder of 2017 and beyond.

In 2016 PBI produced five machines which were chosen to go to the cancer research project Cancer Moonshot, a project formerly led by Vice President Joe Biden, which aims to make more therapies available to more patients, while also improving the ability to prevent cancer to aid in and its early detection.

The Company continues to meet or exceed its goals, and continues to give guidance that it anticipates an up-listing to a major exchange within the next few months, after it completes a planned secondary offering.

Table with 4 columns: Income Statement, Balance Sheet, Cash Flow Statement, and financial data for FY 2014, FY 2015, and FY 2016.



Sector: Healthcare
Industry: Medical Devices & Technology

Website: www.pressurebiosciences.com

Key Statistics

Table listing key statistics such as Price, 52 Week High, Avg. Vol, Beta, Market Cap, etc.

Source: Google / Yahoo Finance

Recent 2017 / 2016 Highlights

- March 23, 2017, PBI announced a significant expansion effort on marketing and sales capabilities.
February 9, 2017, PBI announced CE Marking for their next-generation Barocycler 2320EXTREME.
December 16, 2016, PBI announced the new Barocycler, has been selected and labeled as an essential technology for use in the Cancer Moonshot Initiative.
November 14, 2016, PBI announced it closed of \$610,000 in a private placement.
July 28, 2016, PBI announced an expanded co-marketing agreement with SCIEX to improve protein quantification in complex samples.

Corporate Contact Information

Pressure BioSciences, Inc.
Richard T. Schumacher, CEO
14 Norfolk Ave. South Easton MA, 02375
Phone: 508-230-1828
www.pressurebiosciences.com

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof.